Therapeutic Advances in Hematology Volume 10: January

Journal Article

Novel treatment approaches and future perspectives in follicular lymphoma:

Sutamtewagul, Grerk; Link, Brian K.

2019 Therapeutic Advances in Hematology

doi:10.1177/2040620718820510 pmid:30719267

Follicular lymphoma (FL) is a common B-cell malignancy characterized by relatively indolent growth and incurability with an expected lifetime course of serial intermittent treatment courses. Many patients with FL have lives shortened by the disease and despite a relatively favorable prognosis...

Download Only

Journal Article

A real-world comparative analysis of carfilzomib and other systemic multiple myeloma chemotherapies in a US community oncology setting:

Rifkin, Robert M.; Medhekar, Rohan; Amirian, E. Susan; Aguilar, Kathleen M.; Wilson, Thomas;

2019 Therapeutic Advances in Hematology

doi:10.1177/2040620718816699 pmid:30719266

Background: Most multiple myeloma (MM) patients ultimately progress, with remission duration decreasing after first relapse. Recently, novel agents have been approved for the treatment of relapsed MM. There is a paucity of real-world data on these treatments. We sought to compare time to next...

Download Only

Journal Article

Epigenetic therapy combinations in acute myeloid leukemia: what are the options?:

Bewersdorf, Jan Philipp; Shallis, Rory; Stahl, Maximilian; Zeidan, Amer M.

2019 Therapeutic Advances in Hematology

doi:10.1177/2040620718816698 pmid:30719265

Epigenetics refers to the regulation of gene expression mainly by changes in DNA methylation and modifications of histone proteins without altering the actual DNA sequence. While epigenetic modifications are essential for normal cell differentiation, several driver mutations in leukemic...

Open Access

Journal Article

Immunotherapy in myeloma: how far have we come?

Franssen, Laurens E.; Mutis, Tuna; Lokhorst, Henk M.; van de Donk, Niels W. C. J.

2019 Therapeutic Advances in Hematology

doi:10.1177/2040620718822660 pmid:30719268

The treatment of multiple myeloma (MM) has evolved substantially over the past decades, leading to a significantly improved outcome of MM patients. The introduction of high-dose therapy, especially, and autologous stem cell transplantation, as well as the development of new drugs, such as...

Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Therapeutic Advances in Hematology Volume 10: January

Related Journals:

Advanced Search

Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Therapeutic Advances in Hematology Volume 10: January

Related Journals:

Our policy towards the use of cookies